Sharma Dibya J, Ganguly Suman, M Rakesh, Batta Akash, Paul Majumder Abhishek
Internal Medicine, Gastroenterology, Silchar Medical College and Hospital, Silchar, IND.
Internal Medicine, Silchar Medical College and Hospital, Silchar, IND.
Cureus. 2023 Apr 25;15(4):e38095. doi: 10.7759/cureus.38095. eCollection 2023 Apr.
Background Unraveling sepsis remains the holy grail of clinical medicine and the commonest cause of in-hospital mortality worldwide. Various newer biomarkers have emerged in recent years that aid in the diagnosis and prognostication of sepsis. However, the widespread use of these is limited by availability, cost, and long turnaround times. Considering the crucial role of hematological parameters in infectious conditions, the present study aimed to evaluate the association of various platelet indices with the severity and outcomes in patients diagnosed with sepsis. Methods This was a single-center, prospective, observational study comprising 100 consecutive patients who fulfilled the selection criteria in the emergency department of a tertiary care hospital from June 2021 to May 2022. All patients underwent history taking, physical examination, and necessary laboratory investigations, including complete blood counts, biochemistry panel, and radiographic and microbiological tests. A detailed assessment of various platelet indices (platelet count, mean platelet volume, and platelet distribution width) was performed, and its association with outcomes was derived. The Sequential Organ Failure Assessment (SOFA) score was recorded for all patients. Results The majority of the study population was male (52%) with a mean age of 48.05±19.27 years. Respiratory infection (38%) was the most common origin of sepsis followed by genitourinary infections in 27%. The mean platelet count on admission was 1.83±1.21 lakhs/mm. The incidence of thrombocytopenia (<1.5 lakhs/ mm) in our study sample was 35%. The overall in-hospital mortality of the study group was 30%. Thrombocytopenia was significantly associated with a higher SOFA score (7.4±3 vs. 3.7±1.9, P<0.05), longer hospital stays (10.8±4.6 vs. 7.8±3.9; p<0.05), and mortality (17 vs. 13; p<0.05). The change in platelet count, platelet distribution width, and mean platelet volume from Day 1 to Day 3 also correlated with outcomes. There was a decrease in platelet count among the non-survivors compared to an increase in platelet count among survivors from Day 1 to Day 3 (p<0.05). Similarly, the change in platelet distribution width showed a decreasing trend among the survivors compared to an increasing trend among the non-survivors (p<0.05). The mean platelet volume of non-survivors increased from Day 1 to Day 3 compared to a downward trend among the survivors (p<0.05). Conclusion Septic patients with thrombocytopenia on admission had a higher SOFA score and were associated with worse outcomes. Additionally, platelet indices, such as platelet distribution width and mean platelet volume, serve as important prognostic markers among sepsis patients. Change in these parameters from Day 1 to Day 3 also correlated with outcomes. These indices are simple and affordable, allowing for their serial assessment to aid in the prognosis of sepsis.
解析脓毒症仍是临床医学的圣杯,也是全球医院内死亡的最常见原因。近年来出现了各种新型生物标志物,有助于脓毒症的诊断和预后评估。然而,这些标志物的广泛应用受到可用性、成本和周转时间长的限制。考虑到血液学参数在感染性疾病中的关键作用,本研究旨在评估各种血小板指标与脓毒症诊断患者的严重程度和预后的相关性。
这是一项单中心、前瞻性、观察性研究,纳入了2021年6月至2022年5月在一家三级医院急诊科符合入选标准的100例连续患者。所有患者均接受病史采集、体格检查及必要的实验室检查,包括全血细胞计数、生化指标、影像学和微生物学检查。对各种血小板指标(血小板计数、平均血小板体积和血小板分布宽度)进行详细评估,并得出其与预后的相关性。记录所有患者的序贯器官衰竭评估(SOFA)评分。
研究人群中大多数为男性(52%),平均年龄为48.05±19.27岁。呼吸道感染(38%)是脓毒症最常见的起源,其次是泌尿生殖系统感染(27%)。入院时平均血小板计数为1.83±1.21万/mm。本研究样本中血小板减少症(<1.5万/mm)的发生率为35%。研究组的总体院内死亡率为30%。血小板减少症与较高的SOFA评分(7.4±3对3.7±1.9,P<0.05)、更长的住院时间(10.8±4.6对7.8±3.9;P<0.05)和死亡率(17对13;P<0.05)显著相关。从第1天到第3天血小板计数、血小板分布宽度和平均血小板体积的变化也与预后相关。与幸存者从第1天到第3天血小板计数增加相比,非幸存者的血小板计数减少(P<0.05)。同样,与非幸存者呈上升趋势相比,幸存者中血小板分布宽度的变化呈下降趋势(P<0.05)。与幸存者呈下降趋势相比,非幸存者的平均血小板体积从第1天到第3天增加(P<0.05)。
入院时伴有血小板减少症的脓毒症患者SOFA评分较高,且预后较差。此外,血小板指标,如血小板分布宽度和平均血小板体积,是脓毒症患者重要的预后标志物。这些参数从第1天到第3天的变化也与预后相关。这些指标简单且经济实惠,可进行连续评估以辅助脓毒症的预后判断。